Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

530 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidences.
Quagliariello V, Rossetti S, Cavaliere C, Di Palo R, Lamantia E, Castaldo L, Nocerino F, Ametrano G, Cappuccio F, Malzone G, Montanari M, Vanacore D, Romano FJ, Piscitelli R, Iovane G, Pepe MF, Berretta M, D'Aniello C, Perdonà S, Muto P, Botti G, Ciliberto G, Veneziani BM, De Falco F, Maiolino P, Caraglia M, Montella M, Iaffaioli RV, Facchini G. Quagliariello V, et al. Among authors: caraglia m. Oncotarget. 2017 May 2;8(18):30606-30616. doi: 10.18632/oncotarget.16725. Oncotarget. 2017. PMID: 28389628 Free PMC article. Review.
The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE).
Facchini G, Caraglia M, Santini D, Nasti G, Ottaiano A, Striano S, Maiolino P, Ruberto M, Fiore F, Tonini G, Budillon A, Iaffaioli RV, Zeppetella GL. Facchini G, et al. Among authors: caraglia m. J Exp Clin Cancer Res. 2007 Sep;26(3):307-12. J Exp Clin Cancer Res. 2007. PMID: 17987788 Clinical Trial.
New treatment approaches in renal cell carcinoma.
Facchini G, Perri F, Caraglia M, Pisano C, Striano S, Marra L, Fiore F, Aprea P, Pignata S, Iaffaioli RV. Facchini G, et al. Among authors: caraglia m. Anticancer Drugs. 2009 Nov;20(10):893-900. doi: 10.1097/CAD.0b013e32833123d4. Anticancer Drugs. 2009. PMID: 19752718 Review.
Zoledronic acid: an unending tale for an antiresorptive agent.
Caraglia M, Marra M, Naviglio S, Botti G, Addeo R, Abbruzzese A. Caraglia M, et al. Expert Opin Pharmacother. 2010 Jan;11(1):141-54. doi: 10.1517/14656560903485664. Expert Opin Pharmacother. 2010. PMID: 20001436 Review.
Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial.
Facchini G, Caraglia M, Morabito A, Marra M, Piccirillo MC, Bochicchio AM, Striano S, Marra L, Nasti G, Ferrari E, Leopardo D, Vitale G, Gentilini D, Tortoriello A, Catalano A, Budillon A, Perrone F, Iaffaioli RV. Facchini G, et al. Among authors: caraglia m. Cancer Biol Ther. 2010 Sep 15;10(6):543-8. doi: 10.4161/cbt.10.6.12611. Epub 2010 Sep 8. Cancer Biol Ther. 2010. PMID: 20657175 Clinical Trial.
Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells.
Grieco P, Franco R, Bozzuto G, Toccacieli L, Sgambato A, Marra M, Zappavigna S, Migaldi M, Rossi G, Striano S, Marra L, Gallo L, Cittadini A, Botti G, Novellino E, Molinari A, Budillon A, Caraglia M. Grieco P, et al. Among authors: caraglia m. J Cell Biochem. 2011 Jan;112(1):341-53. doi: 10.1002/jcb.22933. J Cell Biochem. 2011. PMID: 21080343
530 results